---
category: news
title: "Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week"
excerpt: "BioXcel Therapeutics is a clinical-stage biopharmaceutical with no review or marketed drugs yet. The company's stock rose more than $4 a share over the course of the week. It's expecting a decision by the FDA regarding its lead therapy by April 5."
publishedDateTime: 2022-03-24T23:00:00Z
originalUrl: "https://www.fool.com/investing/2022/03/24/why-shares-of-bioxcel-therapeutics-shot-up-254-thi/"
webUrl: "https://www.fool.com/investing/2022/03/24/why-shares-of-bioxcel-therapeutics-shot-up-254-thi/"
type: article
quality: 54
heat: 54
published: false

provider:
  name: The Motley Fool
  domain: fool.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/fool.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://g.foolcdn.com/editorial/images/671878/alzheimers.jpg"
    width: 2121
    height: 1414
    isCached: true

secured: "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;8lqMoWOYA/V+pjOLEE9GGA=="
---

